Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral antiresorptive therapy.

Ira Pande1, David J Hosking

  • 1Department of Medicine, City Hospital, Hucknall Road, Nottingham NG5 1PB, United Kingdom.

Current Rheumatology Reports
|March 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secukinumab-induced hepatitis and renal vasculitis.

Rheumatology (Oxford, England)·2026
Same author

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2023
Same author

Sjogren's myelitis presenting as hemicord syndrome.

Clinical medicine (London, England)·2023
Same author

Trials and tribulations in managing a complex case of psoriatic arthritis-a success story in the real world.

Rheumatology advances in practice·2022
Same author

Zoledronate.

Bone·2020
Same author

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?

Rheumatology (Oxford, England)·2017

Newer oral antiresorptive agents, like ibandronate, offer improved osteoporosis management through flexible dosing and administration. Their use is expanding to other conditions, but direct fracture endpoint comparisons are lacking.

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Osteoporosis Management

Background:

  • Oral antiresorptive agents are crucial for osteoporosis treatment.
  • Newer agents and administration routes enhance patient compliance and tolerability.
  • These agents are increasingly used for bone loss in conditions like organ transplantation and cystic fibrosis.

Purpose of the Study:

  • To discuss the effects and future role of newer oral antiresorptive agents, focusing on ibandronate.
  • To explore alternative dosing and administration for improved long-term osteoporosis management.
  • To review the application of antiresorptive agents in other diseases and the combination therapy with anabolic agents.

Main Methods:

  • Review of current literature on oral antiresorptive agents.

Related Experiment Videos

  • Discussion of ibandronate's efficacy and potential.
  • Analysis of studies on extended use in chronic inflammatory diseases and combination therapies.

    • Main Results:

    • Alternative dosing and administration of antiresorptive agents may improve fracture protection, compliance, and tolerability.
    • Antiresorptive agents show promise in managing bone loss in organ transplantation and cystic fibrosis.
    • Combining antiresorptive agents with anabolic agents like teriparatide yielded disappointing results.

    Conclusions:

    • Newer oral antiresorptive agents offer improved osteoporosis management options.
    • The use of antiresorptive agents is expanding to other chronic diseases with high osteoporosis risk.
    • A significant gap exists in direct comparative studies evaluating fracture endpoints among these agents.